RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Lucira Health Stock

Lucira Health P/E 2024

Lucira Health P/E

-0.12

Ticker

LHDXQ

ISIN

US54948U1051

As of Oct 3, 2024, Lucira Health's P/E ratio was -0.12, a 0% change from the 0 P/E ratio recorded in the previous year.

The Lucira Health P/E history

Lucira Health Aktienanalyse

What does Lucira Health do?

Lucira Health is an American company specializing in the development and manufacturing of diagnostic devices and kits. It was founded in 2013 and is headquartered in Emeryville, California. The company was founded by Dr. Erik Engelson and Dr. Jessie Zhou, both of whom have experience in developing molecular diagnostic tests. Lucira Health initially provided research and development services for other companies before deciding to develop its own products. In 2018, the company won first place in the XPRIZE Rapid-Response COVID-19 competition and received a $5 million award for the development of a rapid COVID-19 test. Lucira Health's business model focuses on the development and manufacturing of diagnostic devices and kits. The company works closely with other organizations to develop faster, more effective, and cost-efficient tests. It also utilizes partnerships and licensing agreements to market its devices and tests. Lucira Health has two main divisions: molecular diagnostics and point-of-care diagnostics. In molecular diagnostics, the company offers a range of tests specifically designed for molecular diagnostics, including tests for diagnosing infectious diseases such as COVID-19, influenza, and hepatitis B and C. In point-of-care diagnostics, Lucira Health specializes in the development of point-of-care diagnostic devices that are designed to deliver fast and accurate test results within minutes. The company has developed the first FDA-approved COVID-19 test kit that can be used at home. The test kit provides results within 30 minutes and requires only a nasal swab. In addition to its diagnostic products, the company has also developed a platform that allows users to submit and track their test results online. In conclusion, Lucira Health is a company focused on the development of diagnostic devices and kits. With its emphasis on molecular and point-of-care diagnostics, the company has developed a range of tests that can be used to diagnose infectious diseases. With its history of collaboration with other organizations and the $5 million award from the XPRIZE Rapid-Response COVID-19 competition, Lucira Health is expected to continue developing innovative products that contribute to the improvement of public health. Lucira Health ist eines der beliebtesten Unternehmen auf Eulerpool.com.

P/E Details

Deciphering Lucira Health's P/E Ratio

The Price to Earnings (P/E) Ratio of Lucira Health is a vital metric that investors and analysts use to determine the company’s market value relative to its earnings. It is calculated by dividing the current stock price by the earnings per share (EPS). A higher P/E ratio could suggest that investors are expecting higher future growth, while a lower ratio may indicate a potentially undervalued company or lower growth expectations.

Year-to-Year Comparison

Assessing Lucira Health's P/E ratio on a yearly basis provides insights into the valuation trends and investor sentiment. An increasing P/E ratio over the years signifies growing investor confidence and expectations for future earnings growth, while a decreasing ratio may reflect concerns over the company's profitability or growth prospects.

Impact on Investments

The P/E ratio of Lucira Health is a key consideration for investors aiming to balance risk and reward. A comprehensive analysis of this ratio, in conjunction with other financial indicators, aids investors in making informed decisions regarding buying, holding, or selling the company’s stocks.

Interpreting P/E Ratio Fluctuations

Fluctuations in Lucira Health’s P/E ratio can be attributed to various factors including changes in earnings, stock price movements, and shifts in investor expectations. Understanding the underlying reasons for these fluctuations is essential for predicting future stock performance and assessing the company's intrinsic value.

Frequently Asked Questions about Lucira Health stock

What is the price-to-earnings ratio of Lucira Health?

The price-earnings ratio of Lucira Health is currently -0.12.

How has the price-earnings ratio of Lucira Health changed compared to last year?

The price-to-earnings ratio of Lucira Health has increased by 0% fallen (meaning "decreased" or "dropped") compared to last year.

What consequences does a high price-earnings ratio have for investors?

A high price-to-earnings ratio indicates that the company's stock is relatively expensive and investors may potentially achieve a lower return.

What does a low price-earnings ratio mean?

A low price-earnings ratio means that the company's stock is relatively cheap and investors may potentially achieve a higher return.

Is the price-earnings ratio of Lucira Health high compared to other companies?

Yes, the price-to-earnings ratio of Lucira Health is high compared to other companies.

How does an increase in the price-earnings ratio of Lucira Health affect the company?

An increase in the price-earnings ratio of Lucira Health would lead to a higher market capitalization of the company, which in turn would lead to a higher valuation of the company.

How does a reduction in the price-to-earnings ratio of Lucira Health affect the company?

A decrease in the price-earnings ratio of Lucira Health would result in a lower market capitalization of the company, which in turn would lead to a lower valuation of the company.

What are some factors that influence the price-earnings ratio of Lucira Health?

Some factors that influence the price-earnings ratio of Lucira Health are the company's growth, financial position, industry development, and the overall economic situation.

How much dividend does Lucira Health pay?

Over the past 12 months, Lucira Health paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Lucira Health is expected to pay a dividend of 0 USD.

What is the dividend yield of Lucira Health?

The current dividend yield of Lucira Health is .

When does Lucira Health pay dividends?

Lucira Health pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Lucira Health?

Lucira Health paid dividends every year for the past 0 years.

What is the dividend of Lucira Health?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Lucira Health located?

Lucira Health is assigned to the 'Health' sector.

Wann musste ich die Aktien von Lucira Health kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Lucira Health from 10/3/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 10/3/2024.

When did Lucira Health pay the last dividend?

The last dividend was paid out on 10/3/2024.

What was the dividend of Lucira Health in the year 2023?

In the year 2023, Lucira Health distributed 0 USD as dividends.

In which currency does Lucira Health pay out the dividend?

The dividends of Lucira Health are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Lucira Health

Our stock analysis for Lucira Health Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Lucira Health Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.